OKYO News
Archived Headlines
- Ocular disease biotech OKYO Pharma slashes proposed ADS offering by 50% ahead of $5 million US IPO 04/26/22
- Ocular disease biotech OKYO Pharma sets terms for $10 million US IPO 04/14/22
- US IPO Weekly Recap: No IPOs in another tumultuous week 03/04/22
- Ocular disease biotech OKYO Pharma files for a $12 million US IPO 03/04/22
US IPO Weekly Recap: 1 small IPO and 1 direct listing begin trading
There was just one small IPO and one direct listing this past week. Although there were no new IPO filings, a few large deals in the pipeline updated their prospectuses, including Corebridge Financial (CRBG), Turo (TURO)...read more
Tiny takeover: Small issuers account for over 60% of 2022 IPO activity
Companies have broadly put listing plans on hold amid the worst IPO sell-off in over a decade, but small issuers are still on the move. So far, 21 of the year’s 34 IPOs (62%) have raised less than $50 million, the highest concentration in over a decade....read more
Drug developer OKYO Pharma raises $2.5 million in Nasdaq listing at $4 per ADS
OKYO Pharma, a preclinical biotech developing a lipidated chemerin peptide for dry eye disease, raised $2.5 million by offering 0.6 million ADSs at $4.00, below the as-converted $4.60 last close of its shares on the LSE (symbol: OKYO). At the offer price, OKYO...read more
Ocular disease biotech OKYO Pharma further slashes deal size by 50% ahead of $3 million US IPO
OKYO Pharma, a preclinical biotech developing a lipidated chemerin analog for dry eye disease, lowered the proposed deal size for its upcoming IPO on Friday. The St. Peter Port, Guernsey-based company now plans to raise $3 million by offering 0.5 million ADSs...read more